Protalix BioTherapeutics, Inc.
Company Stats
- Market Cap
- $222.4M
- as of Sep 30, 2026
- Shares Outstanding
- 80.6M
- Free Float
- 79.2%
Income Statement
- Revenue
- $52.7M
- Operating Income
- -$5.5M
- Net Income
- -$6.6M
- EBITDA
- -$4.0M
- Revenue Growth, 3Y
- 3.5%
- FCF Margin, 3Y Avg
- -5.3%
- FCF Margin, Worst Year
- -25.8%
Cash Flow
- Free Cash Flow
- -$13.6M
- FCF Yield
- -6.1%
- Owner FCF Yield
- -7.2%
Balance Sheet
- Cash & Equivalents
- $14.7M
Returns & Capital
- SBC, 3Y Avg
- $3.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $52.7M | -$13.6M | -25.8% |
| FY2024 | $53.4M | $7.4M | 13.8% |
| FY2023 | $65.5M | -$2.5M | -3.8% |
| FY2022 | $47.6M | -$25.6M | -53.8% |
| FY2021 | $38.4M | -$11.7M | -30.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 9, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges